Pembrolizumab and bevacizumab for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (specific types only).
- Your cancer is platinum-sensitive or platinum-resistant, and you have had no more than 4 prior treatment “lines” (some maintenance treatments don’t count as extra lines).
- Your overall health is good enough for treatment (ECOG 0–1) and you have measurable tumors on scans.
- You can have enough blood and organ function for treatment (blood counts, kidney function, liver tests, and albumin meeting the study limits).
- You must be willing to get a tumor biopsy before starting and again after about 3 cycles (if possible).
- You cannot be “platinum-refractory,” and you must not have certain recent treatments or conditions (like recent immunotherapy, untreated brain metastases, or serious uncontrolled infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug called torvutatug samrotecan, alone or with bevacizumab, as a maintenance therapy after chemotherapy for ovarian cancer that has come back. It aims to help keep the cancer from growing for a longer time.
This trial tests a combination of drugs (adebrelimab, chemotherapy, bevacizumab, and fluzoparib) for ovarian cancer that has returned after a period of remission. It may help by using the immune system and targeted therapy to attack cancer cells.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
Hear when a new Recurrent Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.